Pharmaceutical Product Supply – Lidocaine Hydrochloride Injection

The contract entails the manufacture and supply of one unit of FDA-approved Lidocaine Hydrochloride Injection, identified by NSN 6505016140068 and NDC 63323-0485-27, produced in full compliance with current good manufacturing practices. The product is destined for delivery to a Department of Defense contractor under a subcontract arrangement, with the Defense Logistics Agency serving as the overseeing agency. The manufacturing facility must adhere strictly to cGMP standards to ensure product safety, potency, and consistency, meeting all regulatory requirements for use in military medical settings. Although the solicitation number and specific point of contact are not provided, the contract was posted on July 16, 2026, and is classified under NAICS code 325412, which corresponds to pharmaceutical preparation manufacturing. The place of performance and office address details are unspecified, indicating flexibility in logistics or that the delivery endpoint is managed through DLA’s established distribution network. The inclusion of precise product identifiers and regulatory mandates underscores the critical nature of the supply, as it supports defense medical operations requiring reliable, approved pharmaceuticals.